Novavax Inc. filings document formal disclosures for a Nasdaq-listed biotechnology company focused on vaccine products, Matrix-M adjuvant technology and partnership-driven development. Recent 8-K reports record operating results, preliminary financial information, licensing arrangements for Matrix-M, Nuvaxovid marketing-authorization transfers, and facility-related agreements.
Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and governance procedures. The filings also identify Novavax common stock, par value $0.01 per share, as listed on The Nasdaq Global Select Market under NVAX.
NOVAVAX INC executive Robert Edward Walker, EVP, R&D, filed an initial ownership report showing equity awards and common stock holdings. The filing lists stock options to purchase 11,500 shares of common stock at $6.97 expiring on March 7, 2033, 22,510 shares at $10.11 expiring on March 3, 2035, and 18,826 shares at $8.39 expiring on March 2, 2036.
He also holds restricted stock units covering 47,600, 29,490 and 26,300 shares of common stock, plus 34,386 shares of common stock directly. Footnotes describe standard vesting schedules over three to four years, tied to continued employment.
Shah Capital files Amendment No. 6 to its Schedule 13D on Novavax, Inc., updating its ownership and activist intentions. The filing shows Shah Capital Management and related entities beneficially owning up to 14,845,097 shares of Novavax common stock, or 9.11% of the company, based on shares outstanding as of February 16, 2026.
Most shares are held through Shah Capital Opportunity Fund LP, which directly owns 14,000,000 shares, while Himanshu H. Shah personally owns 125,359 shares. The amendment discloses that all shares, other than Mr. Shah’s personal holdings, were acquired using investment capital through open-market purchases.
The filing also notes an April 8, 2026 open letter from Shah Capital to Novavax’s board stating its intention to vote against board nominees and executive compensation. The letter cites concerns such as value destruction, a pessimistic 2026 revenue forecast, low institutional credibility, cost discipline and profitability, and governance changes.
The Vanguard Group amended its Schedule 13G/A to report that it beneficially owns 0 shares of Novavax Inc. common stock, representing 0% of the class.
The amendment explains an internal realignment effective January 12, 2026 and states certain subsidiaries will report holdings separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/27/2026.
Novavax Inc. director John W. Shiver exercised restricted stock units and received additional common shares as part of his equity compensation. On March 10, 2026, he converted 7,947 RSUs into 7,947 shares of Novavax common stock at a price of $0.00 per share.
Following the transactions, Shiver directly holds 7,947 shares of common stock and 15,893 restricted stock units. The RSUs from this grant are scheduled to vest in three equal installments on each of the first three anniversaries of March 10, 2025, assuming he continues to serve on Novavax’s board through each vesting date.
Novavax EVP, CFO and Treasurer James Patrick Kelly reported equity award activity involving restricted stock units (RSUs) and common stock. On March 7, 2026, 12,223 RSUs were exercised and converted into 12,223 shares of Novavax common stock at a stated price of $0.0000 per share.
On the same date, 5,904 shares of common stock were withheld by the company at $9.98 per share to satisfy tax withholding obligations related to the RSU vesting, as noted in the footnotes. After these transactions, Kelly directly held 130,599 shares of Novavax common stock. A related footnote states that one-third of the RSUs from this grant vest on each of the first three anniversaries of the March 7, 2023 grant date, subject to continued employment.
Novavax Executive Vice President, CFO and Treasurer James Patrick Kelly reported an amended insider filing reflecting a grant of 194,000 non‑statutory stock options awarded on March 2, 2026. One-quarter of the options vest on the first anniversary of that date, with the remaining three-quarters vesting in equal monthly installments over the following three years, all conditioned on continued employment. The amendment only updates the exercise price previously reported; all other details remain the same, and the options are held directly.
NOVAVAX INC executive vice president of research and development Ruxandra Draghia-Akli reported an amended insider filing related to a previously disclosed stock option grant. On March 2, 2026, she was granted a non-statutory stock option covering 139,500 shares, held directly.
According to the filing, this Form 4/A was filed solely to amend the exercise price previously reported; all other information from the original March 5, 2026 Form 4 remains unchanged. One quarter of the option vests on the first anniversary of March 2, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued employment.
Novavax Inc. executive Mark J. Casey reported an amended stock option grant. The Form 4/A updates only the exercise price originally reported for a non-statutory stock option covering 152,000 shares that was granted on March 2, 2026; all other details from the earlier filing remain the same.
The option was granted at no cash cost per option share and is held directly. One quarter of the 152,000 option shares vests on the first anniversary of March 2, 2026, and the remaining three quarters vest in equal monthly installments over the following three years, subject to continued employment.
NOVAVAX INC director and President and CEO John C. Jacobs reported a grant of 551,500 non-statutory stock options on March 2, 2026. This Form 4/A solely amends the exercise price originally reported in the prior Form 4; all other details are unchanged.
One quarter of the option vests on the first anniversary of March 2, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued employment.
Novavax executive Elaine O’Hara, EVP and Chief Strategy Officer, filed an amended Form 4 to correct the exercise price previously reported for a 2026 non-statutory stock option grant covering 177,500 shares awarded on March 2, 2026. All other details from the earlier filing remain unchanged.
Under this option, one-quarter of the shares vest on the first anniversary of March 2, 2026, and the remaining three-quarters vest in equal monthly installments over the following three years, subject to her continued employment with the company.